Skip to main content
Top
Published in: BMC Public Health 1/2024

Open Access 01-12-2024 | Respiratory Syncytial Virus Infection | Research

Cost of illness due to respiratory syncytial virus acute lower respiratory tract infection among infants hospitalized in Argentina

Authors: Julia Dvorkin, Emiliano Sosa, Elizabeth Vodicka, Ranju Baral, Andrea Sancilio, Karina Dueñas, Andrea Rodriguez, Carlos Rojas-Roque, Patricia B. Carruitero, Fernando P. Polack, Clint Pecenka, Romina Libster, Mauricio T. Caballero

Published in: BMC Public Health | Issue 1/2024

Login to get access

Abstract

Background

Information is scarce regarding the economic burden of respiratory syncytial virus (RSV) disease in low-resource settings. This study aimed to estimate the cost per episode of hospital admissions due to RSV severe disease in Argentina.

Methods

This is a prospective cohort study that collected information regarding 256 infants under 12 months of age with acute lower respiratory tract infection (ALRTI) due to RSV in two public hospitals of Buenos Aires between 2014 and 2016. Information on healthcare resource use was collected from the patient’s report and its associated costs were estimated based on the financial database and account records of the hospitals. We estimated the total cost per hospitalization due to RSV using the health system perspective. The costs were estimated in US dollars as of December 2022 (1 US dollar = 170 Argentine pesos).

Results

The mean costs per RSV hospitalization in infants was US$587.79 (95% confidence interval [CI] $535.24 – $640.33). The mean costs associated with pediatric intensive care unit (PICU) admission more than doubled from those at regular pediatric wards ($1,556.81 [95% CI $512.21 – $2,601.40] versus $556.53 [95% CI $514.59 – $598.48]).

Conclusions

This study shows the direct economic impact of acute severe RSV infection on the public health system in Argentina. The estimates obtained from this study could be used to inform cost-effectiveness analyses of new preventive RSV interventions being developed.
Appendix
Available only for authorised users
Literature
1.
go back to reference Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399:2047–64.CrossRefPubMedPubMedCentral Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399:2047–64.CrossRefPubMedPubMedCentral
2.
go back to reference Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390:946–58.CrossRefPubMedPubMedCentral Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390:946–58.CrossRefPubMedPubMedCentral
4.
go back to reference Srikantiah P, Vora P, Klugman KP. Assessing the Full Burden of Respiratory Syncytial Virus in Young Infants in Low- and Middle-Income Countries: The Importance of Community Mortality Studies. Clin Infect Dis. 2021;73:S177–9.CrossRefPubMedPubMedCentral Srikantiah P, Vora P, Klugman KP. Assessing the Full Burden of Respiratory Syncytial Virus in Young Infants in Low- and Middle-Income Countries: The Importance of Community Mortality Studies. Clin Infect Dis. 2021;73:S177–9.CrossRefPubMedPubMedCentral
5.
6.
go back to reference Caballero MT, Bianchi AM, Grigaites SD, et al. Community mortality due to respiratory syncytial virus in argentina: population-based surveillance study. Clin Infect Dis. 2021;73:S210–7.CrossRefPubMedPubMedCentral Caballero MT, Bianchi AM, Grigaites SD, et al. Community mortality due to respiratory syncytial virus in argentina: population-based surveillance study. Clin Infect Dis. 2021;73:S210–7.CrossRefPubMedPubMedCentral
7.
go back to reference Gill CJ, Mwananyanda L, MacLeod WB, et al. Infant deaths from respiratory syncytial virus in Lusaka, Zambia from the ZPRIME study: a 3-year, systematic, post-mortem surveillance project. Lancet Glob Health. 2022;10:e269–77.CrossRefPubMedPubMedCentral Gill CJ, Mwananyanda L, MacLeod WB, et al. Infant deaths from respiratory syncytial virus in Lusaka, Zambia from the ZPRIME study: a 3-year, systematic, post-mortem surveillance project. Lancet Glob Health. 2022;10:e269–77.CrossRefPubMedPubMedCentral
8.
go back to reference Simões EAF, Dani V, Potdar V, et al. Mortality From Respiratory Syncytial Virus in Children Under 2 Years of Age: a prospective community cohort study in rural Maharashtra. India Clinical Infectious Diseases. 2021;73:S193-202.CrossRefPubMed Simões EAF, Dani V, Potdar V, et al. Mortality From Respiratory Syncytial Virus in Children Under 2 Years of Age: a prospective community cohort study in rural Maharashtra. India Clinical Infectious Diseases. 2021;73:S193-202.CrossRefPubMed
9.
go back to reference Zhang S, Akmar LZ, Bailey F, et al. Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: a systematic review and meta-analysis. J Infect Dis. 2020;222:S680–7.CrossRefPubMed Zhang S, Akmar LZ, Bailey F, et al. Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: a systematic review and meta-analysis. J Infect Dis. 2020;222:S680–7.CrossRefPubMed
10.
go back to reference Geoghegan S, Erviti A, Caballero MT, et al. Mortality due to respiratory syncytial virus. Burden and risk factors. Am J Respir Crit Care Med. 2017;195:96–103.CrossRefPubMed Geoghegan S, Erviti A, Caballero MT, et al. Mortality due to respiratory syncytial virus. Burden and risk factors. Am J Respir Crit Care Med. 2017;195:96–103.CrossRefPubMed
11.
go back to reference Group* TIm-RS. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics. 1998;102:531–7.CrossRef Group* TIm-RS. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics. 1998;102:531–7.CrossRef
12.
go back to reference COMMITTEE ON INFECTIOUS DISEASES AND BRONCHIOLITIS GUIDELINES COMMITTEE, Brady MT, Byington CL, et al. Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics. 2014;134:415–20.CrossRef COMMITTEE ON INFECTIOUS DISEASES AND BRONCHIOLITIS GUIDELINES COMMITTEE, Brady MT, Byington CL, et al. Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics. 2014;134:415–20.CrossRef
13.
go back to reference Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. Lancet Public Health. 2017;2:e367–74.CrossRefPubMedPubMedCentral Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. Lancet Public Health. 2017;2:e367–74.CrossRefPubMedPubMedCentral
15.
go back to reference Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022;386:837–46.CrossRefPubMed Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022;386:837–46.CrossRefPubMed
17.
go back to reference Dvorkin J, De Luca J, Alvarez-Paggi D, Caballero MT. Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies. Infect Drug Resist. 2023;16:595–605.CrossRefPubMedPubMedCentral Dvorkin J, De Luca J, Alvarez-Paggi D, Caballero MT. Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies. Infect Drug Resist. 2023;16:595–605.CrossRefPubMedPubMedCentral
19.
go back to reference Wittenauer R, Pecenka C, Baral R. Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective. BMC Med. 2023;21:121.CrossRefPubMedPubMedCentral Wittenauer R, Pecenka C, Baral R. Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective. BMC Med. 2023;21:121.CrossRefPubMedPubMedCentral
20.
go back to reference Marcone DN, Durand LO, Azziz-Baumgartner E, et al. Incidence of viral respiratory infections in a prospective cohort of outpatient and hospitalized children aged ≤5 years and its associated cost in Buenos Aires. Argentina BMC Infect Dis. 2015;15:447.CrossRefPubMed Marcone DN, Durand LO, Azziz-Baumgartner E, et al. Incidence of viral respiratory infections in a prospective cohort of outpatient and hospitalized children aged ≤5 years and its associated cost in Buenos Aires. Argentina BMC Infect Dis. 2015;15:447.CrossRefPubMed
22.
go back to reference Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29:653–71.CrossRefPubMed Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29:653–71.CrossRefPubMed
23.
go back to reference Mejia N, Ramani E, Pallas SW, Song D, Abimbola T, Mogasale V. Methodological considerations for cost of illness studies of enteric fever. Clin Infect Dis. 2020;71:S111–9.CrossRefPubMedPubMedCentral Mejia N, Ramani E, Pallas SW, Song D, Abimbola T, Mogasale V. Methodological considerations for cost of illness studies of enteric fever. Clin Infect Dis. 2020;71:S111–9.CrossRefPubMedPubMedCentral
24.
go back to reference Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–81.CrossRefPubMed Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–81.CrossRefPubMed
25.
go back to reference Rubinstein A, Zerbino MC, Cejas C, López A. Making Universal Health Care Effective in Argentina: a blueprint for reform. Health Syst Reform. 2018;4:203–13.CrossRefPubMed Rubinstein A, Zerbino MC, Cejas C, López A. Making Universal Health Care Effective in Argentina: a blueprint for reform. Health Syst Reform. 2018;4:203–13.CrossRefPubMed
26.
go back to reference Macinko J, Montenegro H, Nebot Adell C, Etienne C. Grupo de Trabajo de Atención Primaria de Salud de la Organización Panamericana de la Salud [Renewing primary health care in the Americas]. Rev Panam Salud Publica. 2007;21:73–84.PubMed Macinko J, Montenegro H, Nebot Adell C, Etienne C. Grupo de Trabajo de Atención Primaria de Salud de la Organización Panamericana de la Salud [Renewing primary health care in the Americas]. Rev Panam Salud Publica. 2007;21:73–84.PubMed
29.
go back to reference Atwell JE, Geoghegan S, Karron RA, Polack FP. Clinical predictors of critical lower respiratory tract illness due to respiratory syncytial virus in infants and children: data to inform case definitions for efficacy trials. J Infect Dis. 2016;214:1712–6.CrossRefPubMed Atwell JE, Geoghegan S, Karron RA, Polack FP. Clinical predictors of critical lower respiratory tract illness due to respiratory syncytial virus in infants and children: data to inform case definitions for efficacy trials. J Infect Dis. 2016;214:1712–6.CrossRefPubMed
31.
32.
go back to reference Ferolla FM, Hijano DR, Acosta PL, et al. Macronutrients during pregnancy and life-threatening respiratory syncytial virus infections in children. Am J Respir Crit Care Med. 2013;187:983–90.CrossRefPubMed Ferolla FM, Hijano DR, Acosta PL, et al. Macronutrients during pregnancy and life-threatening respiratory syncytial virus infections in children. Am J Respir Crit Care Med. 2013;187:983–90.CrossRefPubMed
33.
go back to reference Caballero MT, Bianchi AM, Nuño A, et al. Mortality associated with acute respiratory infections among children at home. J Infect Dis. 2019;219:358–64.CrossRefPubMed Caballero MT, Bianchi AM, Nuño A, et al. Mortality associated with acute respiratory infections among children at home. J Infect Dis. 2019;219:358–64.CrossRefPubMed
35.
go back to reference Caballero MT, Polack FP, Stein RT. Viral bronchiolitis in young infants: new perspectives for management and treatment. Jornal de Pediatria. 2017;93:75–83.CrossRefPubMed Caballero MT, Polack FP, Stein RT. Viral bronchiolitis in young infants: new perspectives for management and treatment. Jornal de Pediatria. 2017;93:75–83.CrossRefPubMed
36.
go back to reference Lucion MF, Juarez MD, Viegas M, et al. Virus respiratorio sincicial: Patrón clínico epidemiológico en niños internados en un hospital pediátrico durante los años 2000–2013. Arch Argent Pediatr. 2014;112:397–404.PubMed Lucion MF, Juarez MD, Viegas M, et al. Virus respiratorio sincicial: Patrón clínico epidemiológico en niños internados en un hospital pediátrico durante los años 2000–2013. Arch Argent Pediatr. 2014;112:397–404.PubMed
37.
go back to reference Marcone DN, Durand LO, Azziz-Baumgartner E, et al. Incidence of viral respiratory infections in a prospective cohort of outpatient and hospitalized children aged ≤5 years and its associated cost in Buenos Aires, Argentina. BMC Infect Dis. 2015;15:447.CrossRefPubMedPubMedCentral Marcone DN, Durand LO, Azziz-Baumgartner E, et al. Incidence of viral respiratory infections in a prospective cohort of outpatient and hospitalized children aged ≤5 years and its associated cost in Buenos Aires, Argentina. BMC Infect Dis. 2015;15:447.CrossRefPubMedPubMedCentral
38.
go back to reference Rodriguez-Martinez CE, Sossa-Briceño MP, Castro-Rodriguez JA. Direct medical costs of RSV-related bronchiolitis hospitalizations in a middle-income tropical country. Allergol Immunopathol. 2020;48:56–61.CrossRef Rodriguez-Martinez CE, Sossa-Briceño MP, Castro-Rodriguez JA. Direct medical costs of RSV-related bronchiolitis hospitalizations in a middle-income tropical country. Allergol Immunopathol. 2020;48:56–61.CrossRef
39.
go back to reference Moyes J, Tempia S, Walaza S, et al. The economic burden of RSV-associated illness in children aged < 5 years, South Africa 2011–2016. BMC Med. 2023;21:146.CrossRefPubMedPubMedCentral Moyes J, Tempia S, Walaza S, et al. The economic burden of RSV-associated illness in children aged < 5 years, South Africa 2011–2016. BMC Med. 2023;21:146.CrossRefPubMedPubMedCentral
40.
go back to reference Baral R, Mambule I, Vodicka E, et al. Estimating the economic impact of respiratory syncytial virus and other acute respiratory infections among infants receiving care at a referral Hospital in Malawi. J Pediatr Infect Dis Soc. 2020;9:738–45.CrossRef Baral R, Mambule I, Vodicka E, et al. Estimating the economic impact of respiratory syncytial virus and other acute respiratory infections among infants receiving care at a referral Hospital in Malawi. J Pediatr Infect Dis Soc. 2020;9:738–45.CrossRef
41.
go back to reference Bhuiyan MU, Luby SP, Alamgir NI, et al. Costs of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010. J Glob Health. 2017;7:010412.PubMedPubMedCentral Bhuiyan MU, Luby SP, Alamgir NI, et al. Costs of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010. J Glob Health. 2017;7:010412.PubMedPubMedCentral
43.
go back to reference Homedes N, Ugalde A. Improving access to pharmaceuticals in Brazil and Argentina. Health Policy Plan. 2006;21:123–31.CrossRefPubMed Homedes N, Ugalde A. Improving access to pharmaceuticals in Brazil and Argentina. Health Policy Plan. 2006;21:123–31.CrossRefPubMed
46.
go back to reference Buendía JA, Patino DG, Sinisterra D. Cost of illness of RSV infection in a middle-income tropical country. Turk J Pediatr. 2021;63:673–82.CrossRefPubMed Buendía JA, Patino DG, Sinisterra D. Cost of illness of RSV infection in a middle-income tropical country. Turk J Pediatr. 2021;63:673–82.CrossRefPubMed
Metadata
Title
Cost of illness due to respiratory syncytial virus acute lower respiratory tract infection among infants hospitalized in Argentina
Authors
Julia Dvorkin
Emiliano Sosa
Elizabeth Vodicka
Ranju Baral
Andrea Sancilio
Karina Dueñas
Andrea Rodriguez
Carlos Rojas-Roque
Patricia B. Carruitero
Fernando P. Polack
Clint Pecenka
Romina Libster
Mauricio T. Caballero
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2024
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-024-17878-3

Other articles of this Issue 1/2024

BMC Public Health 1/2024 Go to the issue